-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Replimune Group, Raises Price Target to $14

Benzinga·02/05/2026 15:48:28
Listen to the news
Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $13 to $14.